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Abstract. 
 
The neural cell adhesion molecule L1 has 
been shown to function as a homophilic ligand in a vari-
ety of dynamic neurological processes. Here we demon-
strate that the sixth immunoglobulin-like domain of hu-
man L1 (L1-Ig6) can function as a heterophilic ligand 
for multiple members of the integrin superfamily in-
cluding 
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, and 
 
a
 
IIb
 
b
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. The interaction be-
tween L1-Ig6 and 
 
a
 
IIb
 
b
 
3
 
 was found to support the rapid 
attachment of activated human platelets, whereas a cor-
responding interaction with 
 
a
 
v
 
b
 
3
 
 and 
 
a
 
v
 
b
 
1
 
 supported 
the adhesion of umbilical vein endothelial cells. Muta-
tion of the single Arg-Gly-Asp (RGD) motif in human 
L1-Ig6 effectively abrogated binding by the aforemen-
tioned integrins. A L1 peptide containing this RGD 
motif and corresponding flanking amino acids (PSIT-
WRGDGRDLQEL) effectively blocked L1 integrin in-
teractions and, as an immobilized ligand, supported ad-
hesion via 
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, and 
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IIb
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. Whereas 
 
b
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integrin binding to L1-Ig6 was evident in the presence 
of either Ca
 
2
 
1
 
, Mg
 
2
 
1
 
, or Mn
 
2
 
1
 
, a corresponding inter-
action with the 
 
b
 
1
 
 integrins was only observed in the 
presence of Mn
 
2
 
1
 
. Furthermore, such Mn
 
2
 
1
 
-dependent 
binding by 
 
a
 
5
 
b
 
1
 
 and 
 
a
 
v
 
b
 
1
 
 was significantly inhibited 
by exogenous Ca
 
2
 
1
 
. Our findings suggest that phys-
iological levels of calcium will impose a hierarchy of in-
tegrin binding to L1 such that 
 
a
 
v
 
b
 
3
 
 or active 
 
a
 
IIb
 
b
 
3 
 
. 
a
 
v
 
b
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. a
 
5
 
b
 
1
 
. Given that L1 can interact with multiple 
vascular or platelet integrins it is significant that we also 
present evidence for de novo L1 expression on blood 
vessels associated with certain neoplastic or inflamma-
tory diseases. Together these findings suggest an ex-
panded and novel role for L1 in vascular and thrombo-
genic processes.
P
 
ioneering 
 
studies on the structure and function of
L1 have established this cell adhesion molecule
(CAM)
 
1
 
 as a member of the immunoglobulin super-
family (IgSF) that plays a quintessential role in neural de-
velopment (Lindner et al., 1983; Moos et al., 1988). Func-
tions attributed to this neural CAM include such dynamic
processes as cerebellar cell migration (Lindner et al., 1983)
and neurite fasciculation and outgrowth (Lagenaur and
Lemmon, 1987).
Human and mouse L1 and L1-related glycoproteins in
the rat (nerve growth factor–inducible, large external gly-
coprotein [NILE]), chick (neuron–glial [Ng]CAM, 8D9,
G4), and 
 
Drosophila
 
 (neuroglia) have been described (Gru-
met et al., 1984; Bock et al., 1985; Lemmon and McLoon,
1986; Mujoo et al., 1986). These homologues share an ex-
tracellular structure consisting of six Ig-like domains and
five fibronectin type III–like repeats (Moos et al., 1988;
Sonderegger and Rathjen, 1992). These extracellular do-
mains are linked via a single transmembrane sequence to a
short, highly conserved cytoplasmic domain (Reid and
Hemperly, 1992). Limited structural variation within the
human L1 molecule has been reported and can be attrib-
uted to variable glycosylation and two alternatively spliced
mini exons (Reid and Hemperly, 1992; Jouet et al., 1995).
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Abbreviations used in this paper
 
: CAM, cell adhesion molecule; GST,
glutathione-S-transferase; IgSF, immunoglobulin super family; L1-Ig6,
sixth immunoglobulin-like domain of human L1; NCAM, neural cell ad-
hesion molecule; NILE, nerve growth factor–inducible, large external pro-
tein; NgCAM, neuron–glial CAM; ORF, open reading frame; PGE
 
1
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taglandin E
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; RGD, Arg-Gly-Asp; VNR, vitronectic receptor.
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Reflecting its designation as a neural CAM (NCAM),
L1 is highly expressed on postmitotic neurons of the cen-
tral and peripheral nervous systems and on pre- or nonmy-
elinating Schwann cells of the peripheral nervous system
(Lindner et al., 1983; Rathjen and Schachner, 1984; Mar-
tini and Schachner, 1986). Although classified a neural
recognition molecule, L1 has also been identified on non-
neuronal cell types of surprisingly diverse origin. Thus, we
and others, have recently described L1 on human immune
cells of both myelomonocytic and lymphoid origin (Ebeling
et al., 1996; Pancook et al., 1997). L1 has also been de-
scribed on epithelial cells of the intestine and urogenital
tract (Thor et al., 1987; Kowitz et al., 1992; Kujat et al.,
1995) and on transformed cells of both neuroectodermal
and epithelial origin (Mujoo et al., 1986; Linnemann et al.,
1989; Reid and Hemperly, 1992). Apart from such cellular
associations it is apparent that L1 can also be shed and in-
corporated into the extracellular matrix (Martini and Schach-
ner, 1986; Poltorak et al., 1990; Montgomery et al., 1996).
This consequently implies a dual function for L1 both as a
CAM and a substrate adhesion molecule (SAM).
In addition to having a propensity for homophilic bind-
ing (Lemmon et al., 1989), L1 has recently emerged as a
ligand that can undergo multiple heterophilic interactions.
Examples include interactions with other members of the
IgSF and even components of the extracellular matrix. Thus,
heterophilic ligands include TAG-1/axonin-1 (Kuhn et al.,
1991; Felsenfeld et al., 1994), F3/F11 (Olive et al., 1995),
laminin (Hall et al., 1997), and chondroitin sulfate proteo-
glycans (Grumet et al., 1993; Friedlander et al., 1994). Sig-
nificantly, L1 has also been reported to undergo multiple
 
cis
 
-type interactions with molecules as diverse as NCAM
(Feizi, 1994), CD9 (Schmidt et al., 1996), and CD24 (Kad-
mon et al., 1995). Interestingly such interactions in the plane
of the cell membrane may serve to modify the specificity
and avidity of L1 binding to ligands associated with the
membranes of juxtaposed cells or the extracellular matrix
(Feizi, 1994; Kadmon et al., 1995; Schmidt et al., 1996).
The presence of a single Arg-Gly-Asp (RGD) motif in
the sixth Ig-like domain of human L1, and the presence of
two such motifs in the same domain of the murine and rat
L1-homologues prompted early speculation as to whether
L1 might also function as a heterophilic ligand for mem-
bers of the integrin superfamily. A number of studies have
now reported novel L1-integrin interactions (Ruppert et al.,
1995; Ebeling et al., 1996; Montgomery et al., 1996; Ducz-
mal et al., 1997; Pancook et al., 1997). In the first of these
studies, Ruppert et al. (1995) describe an interaction be-
tween the integrin 
 
a
 
5
 
b
 
1
 
 and murine L1. In a subsequent
study, we report an interaction between human L1 and the
vitronectin receptor 
 
a
 
v
 
b
 
3
 
 (Montgomery et al., 1996); an as-
sociation that has now been described using a variety of
cell types (Ebeling et al., 1996; Pancook et al., 1997; Ducz-
mal et al., 1997). Whereas an interaction between the inte-
grin 
 
a
 
5
 
b
 
1
 
 and murine L1 has been documented, an interac-
tion between this integrin and human L1 has not, despite
the use of cells expressing reasonable levels of this integrin
(Ebeling et al., 1996). This has prompted some debate
about species-specific recognition perhaps governed by
the presence of an additional RGD site in murine L1 (Ebel-
ing et al., 1996). Whereas the majority of these studies have
used purified or recombinant L1 as a substrate for inte-
 
grin-mediated adhesion, it is important that the interaction
between integrin 
 
a
 
5
 
b
 
1
 
 and murine L1 has also been shown
to mediate cell–cell interaction (Ruppert et al., 1995).
To date, 
 
a
 
v
 
b
 
3
 
 is the only member of the integrin super-
family that has been shown to interact with human L1
(Ebeling et al., 1996; Montgomery et al., 1996; Duczmal et
al., 1997; Pancook et al., 1997). A primary objective of this
study was to determine whether recognition of human L1
is a singular attribute of 
 
a
 
v
 
b
 
3
 
 or an attribute that can be ex-
tended to other RGD-dependent integrins. In this regard,
we demonstrate that the sixth Ig-like domain of human L1
can in fact support multiple integrin interactions involving,
not just 
 
a
 
v
 
b
 
3
 
, but also the integrins 
 
a
 
v
 
b
 
1
 
, 
 
a
 
IIb
 
b
 
3
 
, and indeed
 
a
 
5
 
b
 
1
 
. A further objective of this study was to address key
structural and regulatory issues related to these L1-inte-
grin interactions, including the central importance of the
single RGD motif and the critical differential effects of spe-
cific divalent cations. In this regard, we present evidence
that recognition of L1 by 
 
a
 
v
 
b
 
3
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a
 
v
 
b
 
1
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a
 
IIb
 
b
 
3
 
, and 
 
a
 
5
 
b
 
1
 
 is in-
deed RGD-dependent and that the binding of these differ-
ent integrins is differentially regulated by physiological
levels of calcium. Based on the novel pairing of L1 with
 
a
 
v
 
b
 
1
 
 or 
 
a
 
IIb
 
b
 
3
 
, we further demonstrated that this CAM can
support the attachment of both endothelial cells (
 
a
 
v
 
b
 
1
 
)
and activated platelets (
 
a
 
IIb
 
b
 
3
 
). Given the interaction be-
tween L1 and the vascular integrins 
 
a
 
v
 
b
 
3
 
 and 
 
a
 
v
 
b
 
1
 
, it is sa-
lient that we also describe de novo L1 expression on blood
vessels associated with certain neoplastic or inflammatory
diseases. Based on these findings we suggest expanded and
novel roles for L1-integrin interactions in vascular and
thrombogenic processes.
 
Materials and Methods
 
Antibodies
 
Anti-integrin antibodies used include the following: anti-hamster 
 
a
 
5
 
b
 
1
 
mAb PB1, anti-
 
a
 
v
 
 and b3 integrin polyclonal (anti-vitronetic receptor
[VNR]), anti-avb3 mAb LM609, anti-aIIbb3 mAb LJ-CP8, anti–b3 integrin
mAb 7E3, anti–b1 integrin mAb P4C10, and anti–av integrin mAb 17E6.
PB1 was generated and provided by Dr. R. Juliano (University of North
Carolina, Chapel Hill, NC), (Brown and Juliano, 1985). Anti–b1 integrin
mAb P4C10 was provided by Dr. E.A. Wayner (University of Minnesota,
Twin Cities, MN). The 7E3 antibody was originally generated and charac-
terized by Coller et al. (1986) and the 17E6 antibody (Mitjans et al., 1995)
was provided by Dr. S.L. Goodman (Merck KGaA, Darmstadt, Germany).
LM609 (Cheresh and Spiro, 1987), anti-VNR, and LJ-CP8 (Niija et al.,
1987) were generated within the Scripps Research Institute (La Jolla,
CA). The anti–human L1 mAb 5G3 used in this study, was also generated
and characterized within the Scripps Research Institute (Mujoo et al.,
1986).
Peptides
L1 peptides were synthesized on a peptide synthesizer (ABI 430A; Ap-
plied Biosystems, Inc., Foster City, CA) within the Scripps Research Insti-
tute Core Facility. A 15-mer peptide was selected to include the single
RGD site in human L1 (i.e., PSITWRGDGRDLQEL). Control peptides
were substituted with alanine to give PSITWRADGRDLQEL. For the
purpose of immobilization an additional batch of these peptides was made
with NH2-terminal cysteine residues. Peptides were prepared using Rink
Amide MBHA or Wang resin (Calbiochem-Novabiochem, La Jolla, CA).
After resin deprotection and assembly the peptides were cleaved from the
resin with a cleavage cocktail (2.5% ethanedithiol, 5% thioanisole, 5%
water, 87.5% trifluoroacetic acid) and subsequently purified by prepara-
tive reverse phase HPLC. Peptides were characterized further by analyti-
cal HPLC and mass spectroscopy.
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Cell Lines and Culture
The generation and characterization of CHO cells stably transfected to
express normal human platelet aIIbb3 (A5 cells) has been described in de-
tail elsewhere (O’Toole et al., 1989, 1990; Frojmovic et al., 1991) and will
be described only briefly here. CHO cells were cotransfected with equal
amounts of human aIIb and b3 expression constructs and a CDM8 vector
containing the neomycin resistance gene CDNeo at a ratio of 30:1 (O’Toole
et al., 1989). Transfection was performed by the calcium phosphate method
followed by glycerol shock. G418-resistant colonies were isolated and pos-
itive clones identified by flow cytometry using subunit-specific antibodies.
The generation of CHO cells transfected to express the active extracellu-
lar domain of aIIbb3 (aIIbaLDb3 cells) has been described (O’Toole et al.,
1994). Briefly, the cytoplasmic sequence from the aL integrin subunit was
isolated from the appropriate cDNA clone by PCR with the PCR oligonu-
cleotides designed to omit the aL cytoplasmic sequence VGFFK (i.e.,
aLD). As previously described, the aLD construct was ligated with a frag-
ment encoding the extracellular and transmembrane domains of the aIIb
integrin subunit. Coexpression of this chimeric internal deletion mutant
(aIIbaLD) with the wild-type b3 integrin subunit resulted in the stable ex-
pression of the aIIbaLDb3 heterodimer bearing an active, high affinity ex-
tracellular domain of human aIIbb3 (O’Toole et al., 1994). Wild-type CHO-K1
cells and transfected cell lines were maintained in DME supplemented
with 10% FCS, 1% glutamine, and 1% non-essential amino acids.
A spontaneously transformed, human umbilical vein endothelial cell
line designated ECV304 (Hughes, 1996) was obtained from the American
Type Culture Collection (Rockville, MD). A stable avb3-negative variant
of this line was obtained by repeated negative sorting using anti-avb3 mAb
LM609. Sorting of avb3-negative unstained cells was performed using a
FACstar® flow cytometer (Becton Dickinson, Co., Mountain View, CA).
To obtain a stable, avb3-negative population, the cells were sorted on five
consecutive occasions. The ECV304 cells were maintained in M199 me-
dium supplemented with 10% FCS and 1% glutamine.
Isolation of Human Platelets
Blood was collected from the antecubital vein of healthy adult donors
through a 19-gauge needle into syringes containing, as anticoagulant the
thrombin inhibitor d-phenylalanyl-l-arginine chloromethyl ketone dihy-
drochloride (PPACK; Bachem Bioscience Inc., Philadelphia, PA) (50 nM
final concentration) and supplemented, when indicated, with prostaglan-
din E1 (PGE1; Sigma Chemical Co., St. Louis, MO) (20 nM final concen-
tration) to inhibit platelet activation. None of the donors had taken drugs
known to affect platelet function for the preceding 10 d. For the prepara-
tion of washed platelets, the blood was supplemented with 5 U/ml of the
ADP scavenger apyrase (Sigma Chemical Co.) and centrifuged at 2,500 g
for 15 min at room temperature. Plasma was removed and replaced with
an equivalent volume of Hepes-Tyrode’s buffer, pH 6.5 (10 mM Hepes,
140 mM NaCl, 2.7 mM KCl, 0.4 mM NaH2PO4, 10 mM NaHCO3, and 5 mM
dextrose), containing 1 U/ml of apyrase. The resuspended blood cells were
centrifuged again at 2,250 g for 10 min. The blood cells were washed twice
using Hepes-Tyrode’s buffer containing 0.2 U/ml apyrase in the next step
and no apyrase in the last step. The final blood cell pellet was reconsti-
tuted in Hepes-Tyrode’s buffer, pH 7.4, containing 50 mg/ml BSA to ad-
just the viscosity to that of plasma, and then centrifuged at 700 g for 15
min. The platelet-rich supernatant was collected and supplemented with
1 mM CaCl2, 1 mM MgCl2, and 100 mM MnCl2. The platelet count was ad-
justed to 100,000 platelets/ml. To analyze the effect of activation on plate-
let adhesion, the platelets were stimulated with ADP and epinephrine (20 mM
final concentration of each) immediately before adding the platelet sus-
pension to the assay plates. Adhesion of non-activated platelets was stud-
ied using unstimulated platelets prepared from PGE1-treated blood.
Construction and Expression of L1 Fusion Proteins
Two wild-type and two mutant L1–glutathione-S-transferase (GST) fu-
sion proteins were used in this study. The wild-type fusion proteins con-
sisted of Ig-like domains 4, 5, and 6 (L1-Ig4-6) or the sixth Ig-like domain
alone (L1-Ig6). The mutant fusion proteins consist of the sixth Ig-like do-
main of L1 with the amino acid mutations of Arg-554 and Asp-556 to Lys-
554, and Glu-556, respectively (i.e., RGDfi KGE) or the single amino acid
mutation Asp-556 to Ala-556 (i.e., RGDfi RGA). Amino acids are num-
bered as described by Bateman et al. (1996).
The generation and characterization of the L1-Ig4-6 GST fusion pro-
tein used in this study has been described in detail elsewhere (Zhao and
Siu, 1995). The production of L1-Ig6 GST fusion protein (amino acids
518–614) was as follows. The region of interest was amplified from full-
length L1 cDNA, which was provided by Dr. J. Hemperly (Becton Dickin-
son Research Center, Research Triangle Park, NC). Amplification was
performed according to the manufacturer’s instructions for the Expand
High Fidelity PCR System (Boehringer Mannheim Corp., Indianapolis,
IN) using an upstream sense primer specific for nucleotides 1,542–1,562 of
the human L1 open reading frame (ORF) and containing an engineered
internal EcoRI restriction endonuclease site (59-AAA GAA TTC ACT
CAG ATC ACT-39) in conjunction with a downstream antisense primer
specific for nucleotides 1,829–1,849 of the human L1 ORF, which was also
engineered to contain an internal EcoRI site (59-CGT GAA TTC GGC
CCA GGG CTC-39). The resulting product was digested with EcoRI and
subcloned into a pGEX-1lT vector (Pharmacia Biotech Sevrage, Upp-
sala, Sweden). Competent Escherichia coli strain BL21 cells (Stratagene,
La Jolla, CA) were transformed with this construct and resulting colonies
were screened by PCR and examined for expression of appropriately
sized GST fusion protein by SDS-PAGE, followed by immunoblotting
with an anti-GST polyclonal antibody (Upstate Biotechnology, Inc., Lake
Placid, NY). The chemiluminescent substrate PS-3 (Lumigen, Inc., South-
field, MI) was used for detection. Dideoxy sequencing of positive clones
was performed to verify the integrity of the introduced coding sequence.
The mutant L1-Ig6 RGDfi RGA was generated according to the man-
ufacturer’s instructions for the Quickchange Site-Directed Mutagenesis
Kit (Stratagene) using the plasmid DNA encoding the L1-Ig6 fusion pro-
tein (pGEX-1lT L1-Ig6) as template. Briefly, oligonucleotides correspond-
ing to the sense and antisense sequences of bases 1,654–1,682 of the L1
ORF, which included a change from A to C at base 1,666 (sense: 59-CCT
GGC GTG GGG CCG GTC GAG ACC TCC AG-39; antisense: 59-CTG
GAG GTC TCG ACC GGC CCC ACG CCA GG-39) were annealed to a
heat-denatured template, and the construct was replicated using Pfu DNA
polymerase for 18 cycles. The resulting mixture was digested with the meth-
ylation-dependent endonuclease DpnI to degrade the wild-type template.
Supercompetent E. coli strain XL-1 blue cells were transformed with this
construct by heat shock and resulting colonies were screened and se-
quenced as described above.
To generate the mutant L1-Ig6 RGDfi KGE the primers for an equiva-
lent L1-Ig6 construct (forward primer: 59-TGG GAT CCA GAT CAC
TCA GGG GC-39; and the reverse primer: 59-GCG AAT TCT GGG
ATC CCG GCC CAG GGC TCC CCA C-39) encoding for amino acids
518–614, were used in conjunction with the mutagenic primers 59-CAT
CAC CTG GAA GGG GGA GGG TCG AGA CC-39 and 59-GTA GTG
GAC CTT CCC CCT CCC AGC TCT GG-39 in the four primer method
(Higuchi, 1990). The amplified product was digested with BamHI and
subcloned into this site of pGEX-3X for expression in the E. coli strain
JM101. The nucleotide sequence of the insert was confirmed by double-
stranded DNA sequencing using the T7 Sequencing™ kit (Pharmacia Bio-
tech Sevrage).
Purification of the recombinant fusion proteins was performed using
isopropylthio-b-d-galactoside–induced log-phase cultures essentially as
described by the manufacturer for the GST Gene Fusion System (Phar-
macia Biotech Sevrage). Briefly, recovered bacteria were lysed by sonica-
tion and incubated with detergent before clarification and immobilization
of the recombinant protein on a Sepharose 4B–coupled, glutathione affin-
ity matrix (Pharmacia Biotech Sevrage). After extensive washing, the
GST fusion proteins were eluted from the matrix with 10 mM reduced glu-
tathione in 50 mM Tris-HCl, pH 8.0, and dialyzed extensively against PBS
before use. The fusion proteins were subject to SDS-PAGE to confirm the
correct mobility and to confirm purity.
Flow Cytometry
Integrin expression was assessed by FACS® analysis. Subconfluent cul-
tures were harvested and stained with anti-integrin mAbs at 20 mg/ml or
polyclonals diluted 1:40. The cells were then treated with an anti–mouse
or anti–rabbit IgG, FITC-conjugated antibody, and were analyzed with a
FACScan® flow cytometer (Becton Dickinson, Co., Mountain View, CA).
Control cells were treated with secondary FITC-conjugated antibody
only.
Adhesion Assays
Adhesion experiments were performed as detailed by Lagenaur and Lem-
mon (1987) with some modifications. Purified L1-GST fusion proteins
(L1-Ig6 or L1-Ig4-6) dialyzed into PBS were spotted (1-ml spots) and
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coated onto the bottom of 96-well Titertek plates (ICN Pharmaceuticals,
Inc., Costa Mesa, CA) as described (Montgomery et al., 1996). Unless oth-
erwise stated, the fusion proteins were offered at a concentration of 40 mg/ml.
Treated and control wells were blocked with 5% BSA for 1–3 h at 378C.
For adhesion studies involving immobilized peptides, wells were pre-
coated overnight with murine IgG2a antibody at 20 mg/ml. Antibody-
treated and washed wells were then incubated with the heterobifunctional
cross-linker, N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP), at 30
mg/ml in PBS for 45 min. These wells were then washed and peptides
added at 100–200 mg/ml for 2–3 h. Control wells received antibody and
SPDP alone. Treated and control wells were blocked with 5% BSA for
1–3 h at 378C.
CHO cells were harvested using EDTA (0.526 mM) in PBS (versene;
Irvine Scientific, Santa Ana, CA) and ECV304 cells with a trypsin-versene
mixture (Biowhittaker, Walkerville, MD). All the cells were then given a
further wash with the EDTA solution to remove residual cations. The
cells were then resuspended in adhesion buffer consisting of HBSS (with-
out calcium and magnesium) supplemented with 10 mM Hepes, and BSA
(0.2–1%), with the pH adjusted to 7.4. Divalent cations were added as in-
dicated in the text and included MnCl2 (0.4 mM), MgCl2 (1–2 mM), and
CaCl2 (1–2 mM). Platelets were harvested and resuspended in Hepes-
Tyrode’s buffer as described above. For inhibition studies, the cells and
platelets were pretreated with polyclonal antibodies (1:30 dilution), mAbs
(80 mg/ml) or peptides (25 mM) for 30 min before the addition of both
cells and inhibitors to pretreated wells. Cells were added at 105/well and
platelets at 5 3 106/well, and then these plates were spun at 700 rpm to
give a continuous monolayer of cells or platelets on the floor of each well.
Endothelial cells and CHO cells were allowed to adhere for 30–40 min at
378C, while the platelets were allowed to adhere for 10 min. At the end of
the assay the wells were carefully washed with PBS, and non-adherent
cells removed under a constant vacuum. Remaining adherent cells were
fixed with 1% paraformaldehyde, and enumerated with the aid of an in-
verted light microscope. Cells were counted per unit area using a 315 high
powered objective and an ocular grid with a minimum of four areas
counted per well. Alternatively, adherent cells or platelets were stained
for 20 min with 1% crystal violet in 0.1 M borate, pH 9.0. Dye was eluted
with 10% acetic acid and its absorbance determined at 600 nm. All exper-
imental treatments were performed in triplicate.
Immunohistochemistry
Frozen sections of normal human skin, squamous cell carcinoma, psoriatic
skin, and synovial tissue from the knee joint of patients diagnosed with
rheumatoid arthritis were stained for the L1 antigen using mAb 5G3 or
for avb3 expression using mAb LM609. Frozen sections were fixed in cold
acetone before removal of endogenous peroxidase with 0.03% H2O2. Sec-
tions were subsequently blocked with 10% goat serum and 1% BSA in
PBS. Primary antibodies were overlaid onto tissue sections at 20 mg/ml.
Control sections were treated with isotype-matched murine IgG at 20 mg/ml.
Sections were incubated with primary antibodies for 30–60 min at room
temperature or overnight at 48C, and after extensive washing were treated
with a secondary anti–mouse IgG biotinylated antibody (LSAB kit; Dako
Corp., Carpinteria, CA) for 30 min. After further washing, tissue sections
were treated with peroxidase-labeled streptavidin for an additional 30 min.
To achieve red or blue-black color the sections were treated with 3-amino-
9-ethylcarbazole (AEC) or Vector VIP substrate (Vector Laboratories,
Burlingame, CA), respectively. For double staining, the first antigen
(avb3) was revealed using one substrate (AEC), and the sections subse-
quently restained for the second antigen (L1) using a different substrate
(Vector VIP).
Results
Characterization of CHO-K1 Cells and Transfectants
Currently, avb3 is the only integrin that has been shown to
interact with human L1 (Ebeling et al., 1996; Montgomery
et al., 1996; Duczmal et al., 1997; Pancook et al., 1997). To
determine whether L1 is also a ligand for the platelet inte-
grin aIIbb3, we used a CHO cell line (A5) genetically al-
tered to express human platelet aIIbb3 (O’Toole et al.,
1989, 1990; Frojmovic et al., 1991). To further determine
whether aIIbb3 needs to be in an active state to recognize
L1 we used a CHO cell line (aIIbaLDb3) transfected to ex-
press aIIbb3 in a constitutively active state (O’Toole et al.,
1994). Activation was achieved by chimerization of extra-
cellular and transmembrane aIIb with a cytoplasmic dele-
tion mutant of the aL integrin subunit (O’Toole et al.,
1994). The integrin profile of these transfected cell lines
and the CHO wild type was determined by flow cytometry
using anti–hamster or anti–human integrin–specific anti-
bodies (Fig. 1 A). A number of salient conclusions can be
drawn from this analysis. First, both transfected cell lines
have been successfully manipulated to express high levels
of human aIIbb3 (LJ-CP8 reactivity). Second, transfection
of the human b3 integrin subunit has also resulted in a
pairing with endogenous hamster av and consequently ex-
pression of chimeric avb3 (LM609 reactivity). Finally, and
of immediate relevance for this study, wild-type and trans-
fected CHO express high levels of endogenous a5b1 (PB-1
reactivity) and endogenous av integrin(s) (VNR reactivity).
Wild-Type and Transfected CHO Cells Display 
Concentration-dependent Adhesion to L1-Ig6
We have previously demonstrated that purified full-length
L1 and a recombinant L1 fusion protein (L1-Ig4-6) can
support the adhesion of melanoma cells via the integrin
avb3 (Montgomery et al., 1996). We further proposed that
it is the sixth Ig-like domain of human L1 that is likely to
be relevant for such adhesion by virtue of the presence of
a single RGD motif in this domain. Based on this proposi-
tion, and for the purposes of this study, we generated a fu-
sion protein consisting of this L1 domain alone (i.e., L1-
Ig6). As a first step, this L1-Ig6 recombinant protein was
tested for its ability to support adhesion by wild-type and
transfected CHO cells.
Importantly, the L1-Ig6 fusion protein supported signifi-
cant concentration-dependent adhesion by all three CHO
cell lines (Fig. 1 B). Furthermore, transfected CHO cells
exhibited greater adhesion than the wild-type CHO-K1
cells (Fig. 1 B). These data clearly indicate the importance
of the sixth Ig-like domain of L1 for mediating cellular ad-
hesion, and also suggest that transfection and expression
of b3 integrins (avb3 and/or aIIbb3) can lead to enhanced
binding to L1-Ig6. Significantly, CHO cells bearing the ac-
tive aIIbb3 (aIIbaLDb3 cells) showed the greatest level of
adhesion, particularly at lower L1-Ig6 concentrations (Fig.
1 B). When offered at saturating concentrations (i.e., .50
mg/ml), L1-Ig6 supported .90% attachment of the aIIbaLDb3
cells in contact with the substrate, resulting in a continuous
monolayer of spreading cells and these cells were resistant
to detachment by the large shear forces generated during
the washing of the 96-well plates. When offered at a satu-
rating concentration, vitronectin gave an equivalent re-
sponse (data not shown).
Wild-type CHO-K1 Cells Interact with L1-Ig6
Using a5b1 and an av Integrin(s) and These
Heterophilic Interactions Are Differentially Regulated 
by Divalent Cations
From the data presented in Fig. 1 B it is evident that the
wild-type CHO-K1 cells can interact with the L1-Ig6 fu-
sion protein. To characterize this wild type adhesion we
looked for evidence of either b1 or av integrin involvement.
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In the presence of Ca21, Mg21, and Mn21, CHO-K1 cell
adhesion was completely abrogated by a VNR polyclonal
antibody, indicating the involvement of one or more av in-
tegrins (Fig. 2 A, left). Despite high levels of a5b1 expres-
sion, a function blocking mAb specific for hamster a5b1
(PB1) had no impact on adhesion in this cation environ-
ment (Fig. 2 A, left). However, in the presence of Mn21
alone, CHO-K1 adhesion to L1-Ig6 could only be abro-
gated using a combination of VNR polyclonal antibody
and the anti-a5b1 mAb PB1 (Fig. 2 A, right). This finding
indicates that in the presence of Mn21 alone, a5b1 can also
recognize human L1-Ig6. However, it is also clear that
binding by a5b1 must be acutely susceptible to inhibition
Figure 1. (A) Integrin profiles of wild-type CHO-K1 cells, of
CHO cells transfected with aIIb and b3 subunits (A5) and of CHO
cells transfected to express active aIIbb3 (aIIbaLDb3 cells). (B) Con-
centration-dependent adhesion of CHO-K1, A5, and aIIbaLDb3
cells to L1-Ig6. (A) Integrin expression is represented by FACS®
histograms. Cells were treated with antibodies to hamster a5b1
(monoclonal PB1), to human avb3 (mAb LM609), to human
aIIbb3 (mAb LJ-CP8), to hamster or human av or b3 integrin sub-
units (polyclonal VNR), or to human b3 integrins (mAb 7E3).
These cells were subsequently stained with fluorescein-conju-
gated goat anti–mouse or goat anti–rabbit antibodies and were
analyzed using a FACScan® flow cytometer. Control cells were
treated with secondary fluorescein-conjugated antibody only. (B)
Wild-type or transfected cells were allowed to adhere to immobi-
lized L1-Ig6 fusion protein offered at concentrations ranging
from 1 to 100 mg/ml. After 30 min non-adherent cells were re-
moved by washing and the remaining adherent cells counted per
unit area with a 315 high powered objective. Experimental treat-
ments were performed in triplicate with a minimum of four areas
counted per well. No significant adhesion was observed on GST
alone and any minimal residual adhesion to BSA-blocked plastic
alone has been subtracted from the cell counts shown. Error bars
represent 61 SD.
Figure 2. Wild-type CHO-K1 cells adhere to L1-Ig6 using an av
integrin(s) and a5b1, and these heterophilic interactions are criti-
cally and differentially regulated by exogenous Ca21. (A) Wild-
type cells were allowed to adhere to immobilized L1-Ig6 fusion
protein in the presence of Ca21 (2 mM), Mg21 (2 mM), and Mn21
(0.4 mM), or in the presence of Mn21 alone (0.4 mM). Some cells
were pretreated with antibody to human avb3 (mAb LM609; 80
mg/ml), to hamster a5b1 (PB1 ascites 1:30) or to VNR (polyclonal
anti-VNR; 1:30), or a combination of antibodies. The level of
control adhesion achieved in the absence of inhibitors is taken as
100%. In the presence of mixed cations this was equivalent to 82
adherent cells per field and in the presence of Mn21 alone this
was equivalent to 255 adherent cells per field. Both, a combina-
tion of the two preceding antibodies. (B) Wild-type cells were al-
lowed to adhere to immobilized L1-Ig6 fusion protein in the pres-
ence of Mn21 (0.4 mM) alone or in the presence of Mn21 (0.4 mM)
and increasing concentrations of Ca21 (0.5–2 mM). Cells were
pretreated with antibody to hamster a5b1 (PB1 ascites 1:30) or to
VNR (polyclonal anti-VNR; 1:30). (C) Wild-type cells were al-
lowed to adhere to immobilized L1-Ig6 fusion protein in the pres-
ence of Ca21 (1 mM) alone, Mg21 (1 mM) alone or Mn21 (0.4 mM)
alone. The L1-Ig6 fusion protein was offered at a concentration
of 40 mg/ml. Cells were allowed to adhere for 30–40 min in the
presence or absence of the antibodies, and adherent cells counted
per unit area with a 315 high powered objective. Experimental
treatments were performed in triplicate with a minimum of four
areas counted per well. Error bars represent 61 SD.
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by either Ca21 or Mg21 since, as stated, we did not observe
a5b1 involvement when all three cations were present in
the adhesion buffer (Fig. 2 A, left).
Since Ca21 has been shown to inhibit b1 integrin ligation
(Kirchhofer, 1991; Mould et al., 1995) we determined
whether this cation was responsible for a lack of a5b1 in-
volvement in a mixed cation environment (Fig. 2 A, left).
To this end, CHO-K1 cells were allowed to adhere to L1-
Ig6 in the presence of Mn21 and increasing concentrations
of exogenous Ca21. To discriminate between a5b1 and av
integrin–dependent binding, the cells were treated with ei-
ther PB1 or anti-VNR antibody. Using this approach, a
significant inverse correlation was observed between the
concentration of exogenous Ca21 and a5b1-dependent
binding (Fig. 2 B) such that the addition of 2 mM calcium
reduced the level of a5b1-dependent binding by .80%
(Fig. 2 B). In contrast, the same concentration of calcium
reduced the av integrin(s)–dependent binding by only 20%.
It is important to note that when the divalent cations
were added to the adhesion buffer individually only Mn21
could support significant wild-type CHO-K1 adhesion (Fig.
2 C). Together these findings indicate, not only an abso-
lute requirement for Mn21, but also a pivotal role for Ca21
in the differential regulation of integrin binding to L1.
CHO Transfectants Use Both avb3 and Activated aIIbb3 
to Interact with L1-Ig6
Thus far, it has been shown that the CHO transfectants
used in this study have been successfully manipulated to
express significant levels of both avb3 and aIIbb3 (Fig. 1 A)
and that these same cells have an increased ability to bind
to the sixth Ig-like domain of L1 (Fig. 1 B). A further se-
ries of experiments was performed to determine whether
these b3 integrins can indeed recognize L1 and, if so, how
the binding of these integrins is regulated.
In contrast to the situation with the wild-type CHO-K1
cells, cells transfected to express avb3 and aIIbb3 (A5 and
aIIbaLDb3 cells) were able to recognize L1 in the presence
of either Ca21 alone or Mg21 alone (Fig. 3 vs. Fig. 2 C).
Most importantly, this de novo adhesion could be attrib-
uted to both the chimeric avb3 and active aIIbb3. Thus,
CHO cells engineered to express active aIIbb3 (aIIbaLDb3
cells) showed significant adhesion to L1-Ig6 in the pres-
ence of Ca21 or Mg21, and this adhesion could only be sig-
nificantly reduced using a combination of antibodies to
both avb3 and aIIbb3 (Fig. 3, bottom). It is important to
note, that in the presence of Ca21 alone, aIIbb3-dependent
binding to L1-Ig6 was only evident in the CHO cells engi-
neered to express active aIIbb3 (aIIbaLDb3 cells). Thus, in
A5 cells bearing aIIbb3 in its resting state, adhesion to L1-
Ig6 in the presence of Ca21 was fully inhibited by mAb
LM609 (i.e., avb3 dependent) with no evident contribution
by aIIbb3 (Fig. 3, top left). This finding implies that aIIbb3-
dependent recognition of L1 requires this integrin to be in
its activated state. However, it is interesting to note that
Mg21 alone is sufficient to activate aIIbb3 binding by the
A5 cells. Thus, the adhesion of these cells, in the presence
of Mg21 alone, could only be abrogated using antibodies to
both aIIbb3 and avb3 (Fig. 3, top right). Because of endoge-
nous av integrin and a5b1 binding, adhesion in the pres-
ence of Mn21 could only be abrogated using a combination
of polyclonal antibodies to both a5b1 and b3 integrins
(VNR and PB1, data not shown). The ability of the differ-
ent cations to support adhesion of the transfected cell lines
was in the order Mn21 . Mg21 . Ca21 (Fig. 3; Mn21 not
shown).
Platelets Interact with L1-Ig6 Via Activated aIIbb3
Having identified activated aIIbb3 as a heterophilic ligand
for L1-Ig6 in our CHO model we wished to determine
whether this integrin will also mediate platelet attachment.
An interaction between L1- and platelet aIIbb3 would then
suggest a novel physiological function in thrombogenic
processes. In this regard, L1 could contribute either as a
cellular ligand expressed on myelomonocytic cells (Pan-
cook et al., 1997), metastatic neuroectodemal tumors (Lin-
nemann et al., 1989), or endothelial cells, or as a shed
ligand in solution or associated with subcellular matrix
(Martini and Schachner, 1986; Poltorak et al., 1990; Mont-
gomery et al., 1996).
In adhesion assays comparable to those performed with
the CHO cells we observed that L1-Ig4-6, L1-Ig6, and the
immobilized L1-derived peptide (C)PSITWRGDGRDL-
QEL could all support the rapid and significant attach-
ment of activated platelets (Fig. 4, A–C). This adhesion
was not affected by anti-avb3 mAb LM609 alone, but was
Figure 3. Both avb3 and activated aIIbb3 can support attachment
to L1-Ig6 and such ligation can occur in the presence of Ca21
or Mg21 alone. CHO cells transfected with the human aIIb and b3
subunits (A5 cells) or transfected to express active aIIbb3 (aIIbaLDb3
cells) were allowed to adhere to immobilized L1-Ig6 fusion pro-
tein in the presence of Ca21 (2 mM), or Mg21 (2 mM) alone.
Some cells were pretreated with antibody to human avb3 (mAb
LM609; 80 mg/ml), or to human aIIbb3 (mAb LJ-CP8; 80 mg/ml)
or with a combination of antibodies. The L1-Ig6 was offered at 40
mg/ml. Cells were allowed to adhere for 40 min in the presence or
absence of the antibodies, and adherent cells counted per unit
area with a 315 high powered objective. Both, a combination of
the two preceding antibodies. Experimental treatments were per-
formed in triplicate with a minimum of four areas counted per
well. Error bars represent 61 SD.
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abrogated by the mAb 7E3, which is a potent function-
blocking antibody, specific for both avb3 and aIIbb3 (Fig. 4,
A–C). The affinity of activated platelets for immobilized
L1-Ig6, and the strong inhibitory effect of mAb 7E3, is
also evident from the photomicrographs presented in Fig.
4, D and E. Together these findings are consistent with a
role for platelet aIIbb3. The contribution of aIIbb3 was also
confirmed using the specific anti-aIIbb3 mAb LJ-CP8, but
this mAb was generally less effective than 7E3 (data not
shown). It is important to note that these results were only
obtained using platelets bearing active aIIbb3 as a result of
stimulation with ADP and epinephrine. Thus, unstimu-
lated platelets, prepared from PGE1-treated blood, showed
only minimal adhesion to L1-Ig4-6 (Fig. 4 A). These data,
like the data obtained using the CHO cells, clearly indicate
that aIIbb3 needs to be in an active conformation to bind
L1. However, as described for other peptides, recognition
of the L1-derived peptide was not fully dependent on
platelet activation (Fig. 4 C). When offered at saturating
concentrations, the L1 fusion proteins supported the rapid
attachment of a uniform monolayer of platelets such that
the majority of platelets offered and in contact with the
substrate appeared to attach (Fig. 4 D). When used as a
positive control, vitronectin supported comparable levels
of platelet attachment (data not shown). However, as with
L1-Ig4-6 significant attachment to vitronectin required
platelet activation.
Endothelial Cells Interact with L1-Ig6 Using avb3
and avb1 and These Heterophilic Interactions Are 
Differentially Regulated by Divalent Cations
L1 is expressed on a variety of cell types known to interact
with endothelium (Ebeling et al., 1996; Pancook et al.,
1997); and shed L1 may also associate with components of
the subendothelial matrix (Hall et al., 1997). This distribu-
tion raises the question of if and how endothelial cells in-
teract with L1. To address this issue we used a transformed
cell line (ECV304) derived from human umbilical vein en-
dothelial cells (Hughes et al., 1996). These wild-type cells
were found to express both avb3 and a high level of b1 inte-
grins (Fig. 5 A, left column). We also detected expression
of avb5 (mAb P1F6) at a median fluorescence comparable
to that found for avb3 (not shown). Consistent with our
findings using the transfected CHO cells, we observed that
endothelial avb3 can also promote adhesion to L1-Ig6 and
this adhesion is evident in the presence of calcium (Fig. 5
B). Adhesion by these wild-type endothelial cells was only
marginally inhibited by the anti–b1 integrin mAb P4C10
(Fig. 5 B). A similar pattern of adhesion was obtained us-
ing primary human dermal microvascular endothelial cells
(Clonetics, San Diego, CA) (data not shown).
Whereas the contribution of avb3 to a variety of vascular
processes is well documented it is also clear that this inte-
grin is either absent or only marginally expressed by quies-
cent endothelial cells (Brooks et al., 1994). Accordingly,
we wished to determine whether L1 could also be recog-
nized by avb3-negative endothelial cells. To address this
we exploited ECV304 endothelial cells that had been re-
peatedly FACS® sorted for a lack of avb3 expression. This
approach proved successful, resulting in the generation of
a stable population of avb3-negative cells (Fig. 5 A, right
column). The levels of avb5 and b1 integrin expression in
these cells remained unchanged (not shown; and Fig. 5 A,
right column). Remarkably, these avb3-negative cells also
showed significant adhesion to L1-Ig6 (Fig. 5 C). How-
ever, in contrast to the wild-type cells, adhesion was unaf-
fected by an antibody to avb3 (LM609) but was fully inhib-
ited by a mAb to b1 integrins (i.e., P4C10) (Fig. 5 C).
Furthermore, such adhesion was also completely abro-
gated with an antibody specific for av integrins (Fig. 5 C).
Together these results are consistent with an interaction
between L1 and endothelial avb1.
Given that both avb3 and avb1 can interact with L1-Ig6,
we wished to determine why avb3 is the dominant integrin
in wild-type ECV304 cell adhesion (Fig. 5 B). In this re-
Figure 4. Activated aIIbb3 can mediate the attachment of plate-
lets to immobilized L1 fusion proteins and the L1-derived pep-
tide (C)PSITWRGDGRDLQEL. (A–C) Stimulated or unstimu-
lated human platelets were allowed to adhere to immobilized L1
fusion proteins (L1-Ig4-6 or L1-Ig6; A and B) or to immobilized,
L1-derived RGD peptide (C). Some of the platelets were pre-
treated with antibody to avb3 (mAb LM609; 80 mg/ml), or to avb3
and aIIbb3 (mAb 7E3; 80 mg/ml). The platelets were allowed to
adhere for 10 min in the presence or absence of the antibodies
and the adherent platelets subsequently stained with crystal vio-
let for quantification. Experimental treatments were performed
in triplicate. Error bars represent 61 SD. (D and E) Photomicro-
graphs of stimulated platelets adhering to L1-Ig6 in the absence
(D) or presence of mAb 7E3 (E). Adherent platelets were
stained with crystal violet and are confined to the circular area
coated with the fusion protein. Individual platelets cannot be dis-
criminated because of their small size and some aggregation. The
platelets were allowed to adhere for 10 min in the presence or ab-
sence of 7E3. Any minimal residual adhesion to BSA-blocked
plastic alone has been subtracted from the OD values shown. Bar,
300 mm.
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gard, we tested the hypothesis that exogenous calcium
may favor the use of avb3 rather than avb1. We observed a
number of facts supporting this hypothesis. First, signifi-
cant avb1 binding could be induced in the wild-type cells,
but only in the presence of Mn21 alone (Fig. 6 A). Thus,
whereas wild-type ECV304 cell adhesion in the presence
of Ca21 could be abrogated with anti-avb3 mAb LM609
(Fig. 5 B), the adhesion of these cells in the presence of
Mn21 alone could only be blocked using a combination of
antibodies reactive with both avb3 and avb1 (i.e., LM609
and P4C10), or with a mAb reactive with both av integrins
(i.e., 17E6) (Fig. 6 A, right). Second, minimal wild-type ad-
hesion was observed in the presence of Ca21 or Mg21
alone and this appeared to be fully dependent upon avb3
(Fig. 6 A). Finally, in an experiment analogous to that per-
formed with the wild-type CHO cells (Fig. 2 B), we ob-
served that the avb1-mediated (Mn21-dependent) adhe-
sion of the sorted, avb3-negative endothelial cells was sig-
nificantly more susceptible to inhibition by exogenous
Ca21 than the wild-type adhesion (Fig. 6 B). Together
these data indicate that in the absence of avb3 expression,
quiescent endothelial cells may use avb1 to bind to L1,
Figure 5. (A) Integrin profiles of wild-type ECV304 human um-
bilical vein endothelial cells or ECV304 cells repeatedly sorted
for a lack of avb3 expression. (B and C) avb3- and avb1-dependent
adhesion of wild-type or sorted ECV304 endothelial cells to L1-
Ig6. (A) Integrin expression is represented by FACS® histograms.
Cells were treated with antibodies to av integrins (mAb 17E6), to
avb3 (mAb LM609), to av or b3 integrin subunits (polyclonal VNR),
or to b1 integrins (mAb P4C10). These cells were subsequently
stained with fluorescein-conjugated goat anti–mouse or goat anti–
rabbit antibodies and were analyzed using a FACScan® flow cy-
tometer. Control cells were treated with secondary fluorescein-
conjugated antibody only. (B and C) Wild-type or sorted cells
were allowed to adhere to immobilized L1-Ig6 fusion protein of-
fered at 40 mg/ml. Adhesion was performed in the presence of
Ca21 (2 mM), Mg21 (2 mM), and Mn21 (0.4 mM). Some cells were
pretreated with antibody to avb3 (mAb LM609; 80 mg/ml), to b1
integrins (mAb P4C10; 80 mg/ml), to av integrins (MAb 17E6; 80
mg/ml), or with a combination of antibodies. After 40 min non-
adherent cells were removed by washing and the remaining
adherent cells counted per unit area with a 315 high powered ob-
jective. Both, a combination of the two preceding antibodies. Ex-
perimental treatments were performed in triplicate with a minimum
of four areas counted per well. Error bars represent 61 SD.
Figure 6. Usage of avb1 by wild-type ECV304 human umbilical
vein endothelial cells is dictated by a requirement for Mn21 and
by inhibition by Ca21. (A) Wild-type ECV304 endothelial cells
were allowed to adhere to immobilized L1-Ig6 in the presence of
Ca21 alone (1 mM), Mg21 alone (1 mM), or Mn21 alone (0.4 mM).
Some cells were pretreated with antibody to avb3 (mAb LM609;
80 mg/ml), to b1 integrins (mAb P4C10; 80 mg/ml), to av integrins
(mAb 17E6; 80 mg/ml), or with a combination of antibodies. (B)
Wild-type or sorted endothelial cells were allowed to adhere to im-
mobilized L1-Ig6 fusion protein in the presence of Mn21 (0.4 mM)
alone or in combination with increasing concentrations of Ca21
(0.5–2 mM). After 40 min non-adherent cells were removed by
washing and the remaining adherent cells counted per unit area
with a 315 high powered objective. Both, refers to a combination
of the two preceding antibodies. Experimental treatments were
performed in triplicate with a minimum of four areas counted per
well. Error bars represent 61 SD.
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however with the induction of avb3 expression, physiologi-
cal levels of calcium are likely to favor the use of this inte-
grin. It is also clear that whereas avb1-mediated adhesion
is susceptible to inhibition by exogenous Ca21, this inhibi-
tion is less pronounced than that seen when adhesion is
mediated via a5b1 (Fig. 2 B).
The Interaction between L1-Ig6 and the b3 or b1 
Integrins Is RGD-dependent
Thus far we have demonstrated that a single Ig-like do-
main of L1 can support multiple integrin interactions. This
same domain contains an RGD integrin recognition motif
that may provide the binding site for all the aforemen-
tioned integrins. However it is also clear that a given RGD
site may or may not support adhesion depending on flank-
ing sequences, conformational restraints and accessibility
(D’Souza et al., 1991; Haas and Plow, 1994). Furthermore,
although avb3, a5b1, avb1, and aIIbb3 have all been re-
ported to interact with RGD motifs, a5b1 and the b3 inte-
grins have also been shown to interact with non-RGD se-
quences (Koivunen et al., 1994). To help address this issue
we generated a 15-mer peptide based on a sequence in the
sixth Ig-like domain of L1 and inclusive of the RGD rec-
ognition motif (i.e., PSITWRGDGRDQEL). This peptide
was tested for its efficacy both as an immobilized ligand
and as soluble inhibitor of L1 integrin binding.
Supporting the concept of a RGD-dependent interac-
tion we observed that our L1-RGD peptide, once immobi-
lized, could support significant endothelial cell attachment
via avb3, and avb1 (Fig. 7, Endothelial) and CHO cell at-
tachment via endogenous a5b1 and transfected aIIbb3 (Fig.
7, CHO). Specific integrin–peptide interactions were con-
firmed using the function blocking antibodies indicated
(Fig. 7). When offered at the same concentration, a control
peptide (C)PSITWRADGRDQEL was ineffective as an
adhesive ligand. However, it should be noted that because
of the conservative glycine to alanine mutation (i.e.,
RGDfi RAD) this control peptide could also support some
attachment but only at significantly higher concentrations
(not shown).
Further support for RGD-dependent interaction with
L1 was obtained using the same L1-RGD peptide as a sol-
uble inhibitor. At a concentration of 25 mM, the peptide
effectively abrogated endothelial cell adhesion to L1-Ig6
in the presence of Mn21 alone (Fig. 8, left). We have previ-
ously demonstrated that adhesion by these cells in the
presence of this cation involves both avb3 and avb1 (Fig. 6
A, right). Likewise, we also observed a complete inhibition
of wild-type CHO-K1 adhesion in the presence of Mn21
(Fig. 8, middle). According to our previous data, this is
consistent with an inhibition of endogenous a5b1 and the
av integrin(s) (Fig. 2 A, right). Adhesion by the CHO cells
transfected to express active aIIbb3 was less sensitive to in-
hibition via the RGD peptide when used at 25 mM (Fig. 8,
right), but could be fully inhibited at higher peptide con-
centrations (not shown). Used at an equivalent concentra-
tion our control peptide was ineffective at preventing ad-
hesion. But again because of the conservative mutation of
this peptide (i.e., RGDfi RAD) this peptide could also in-
hibit attachment at high concentrations (e.g., 250 mM).
Aforementioned work with the L1-RGD peptide sup-
ports the concept of a RGD-dependent interaction be-
tween integrins and L1. However, to address this issue
definitively, we sought to demonstrate that mutation of the
RGD site in L1-Ig6 is sufficient to abrogate integrin bind-
ing. To this end, we generated additional L1-Ig6 fusion
proteins containing the mutations RGDfi KGE or RGDfi
RGA. Importantly, the conservative RGDfi KGE muta-
tion completely abrogated avb3- and avb1-dependent bind-
ing by the endothelial cells (Fig. 9, Endothelial). This same
mutation and the RGDfi RGA mutation also significantly
abrogated a5b1-dependent binding by wild-type CHO cells
(Fig. 9, CHO, wild-type). Some residual low level binding
to both mutations was still observed, perhaps indicating
that the mutated sequences can still be recognized to some
Figure 7. All of the integrins characterized can
recognize the L1-derived peptide (C)PSIT-
WRGDGRDLQEL. Wild-type or sorted ECV304
endothelial cells and wild-type or transfected CHO
cells (aIIbaLDb3 cells) were allowed to adhere to
immobilized 16-mer peptide (C)PSITWRGD-
GRDLQEL or to control peptide (C)PSITWR-
ADGRDLQEL. Adhesion was performed in the
presence of Ca21 (2 mM), Mg21 (2 mM), and
Mn21 (0.4 mM) or in the presence of Mg21 (1
mM) alone, or Mn21 alone (0.4 mM). Some cells
were pretreated with antibody to human aIIbb3
(mAb LJ-CP8; 80 mg/ml), to avb3 (mAb LM609;
80 mg/ml), to b1 integrins (mAb P4C10; 80 mg/
ml), to av integrins (mAb 17E6; 80 mg/ml), to
hamster a5b1 (PB1 ascites 1:30) or to VNR (poly-
clonal anti-VNR; 1:30), or with a combination of
antibodies. After 40 min, non-adherent cells were
removed by washing and the remaining adherent
cells stained with crystal violet. Both, a combina-
tion of the two preceding antibodies. Experimen-
tal treatments were performed in triplicate with a
minimum of four areas counted per well. Error
bars represent 61 SD.
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degree by a5b1. Alternatively, a second a5b1-binding motif
may exist within the L1-Ig6 domain. Interestingly the
RGDfi KGE mutation could still be recognized to a signif-
icant level by aIIbb3 (Fig. 9, CHO, Active aIIbb3). However,
the alanine substitution mutant (RGA) was sufficient to
fully abrogate aIIbb3-mediated binding.
L1 Expression Can Be Induced on Endothelial Cells
In Vivo
We have identified a variety of endothelial and platelet in-
tegrins that can interact with the sixth Ig-like domain of
L1. Such heterophilic interactions prompted us to deter-
mine whether L1 can be expressed on endothelial cells.
This expression would suggest the potential for L1 integrin
interactions in vascular processes such as angiogenesis and
thrombosis; these are processes that require homotypic or
heterotypic (platelet) interactions involving endothelial
cells.
To address this issue, we looked for L1 expression on
normal or quiescent blood vessels and on activated or an-
giogenic vessels associated with neoplastic or inflamma-
tory diseases. In normal human skin, L1 was absent or
minimally expressed by the dermal vessels (Fig. 10 G).
However, significant expression of L1 was observed on
vessels proximal to a squamous cell carcinoma (Fig. 10, A
and B). These proximal vessels also expressed high levels
of avb3 (Fig. 10 C); a documented marker of angiogenic
blood vessels (Brooks et al., 1994). Importantly, avb3 and
its heterophilic ligand L1, could be colocalized on these
angiogenic blood vessels (Fig. 10, D and E). It is important
to note, that L1 was not detected on all the angiogenic ves-
sels identified by avb3 (Fig. 10, D and E); and that whereas
avb3 expression was evident on intra-tumor vessels, L1 was
only detected on angiogenic vessels in normal skin tissue
peripheral to the tumor (Fig. 10 F). This pattern of expres-
sion may indicate the induction of L1 expression during a
limited phase of blood vessel maturation. In a preliminary
analysis, we did not detect L1 on vessels associated with ei-
Figure 8. Integrin-dependent adhesion to L1-Ig6 can be abro-
gated or reduced using soluble L1-derived peptide PSITWRG-
DGRDLQEL. Wild-type ECV304 endothelial cells and wild-
type or transfected CHO cells (aIIbaLDb3 cells) were allowed to
adhere to immobilized L1-Ig6. Some cells were pretreated and
subsequently adhered in the presence of the soluble peptide
PSITWRGDGRDLQEL (25 mM) or the control peptide
PSITWRADGRDLQEL (25 mM). Some CHO cells were pre-
treated with antibody to human aIIbb3 (mAb LJ-CP8; 80 mg/ml).
Adhesion was performed in the presence of Mg21 (1 mM) alone,
or Mn21 alone (0.4 mM). After 40 min, non-adherent cells were
removed by washing and the remaining adherent cells counted
per unit area with a 315 high powered objective. The level of
control adhesion achieved in the absence of peptide inhibitors
was taken as 100%. In the case of wild-type endothelial and CHO
cells this was equivalent to 188 and 160 adherent cells per field,
respectively; in the case of the CHO cells bearing active aIIbb3,
this was equivalent to 232 adherent cells per field. Experimental
treatments were performed in triplicate with a minimum of four
areas counted per well. Results are expressed as a percent of the
adhesion observed in the absence of peptide. Error bars repre-
sent 61 SD.
Figure 9. Mutation of the RGD sequence in the
sixth Ig-like domain of L1 abrogates binding by
avb3, avb1, and aIIbb3 and reduces binding medi-
ated by a5b1. Wild-type or sorted ECV304 en-
dothelial cells and wild-type or transfected CHO
cells (aIIbaLDb3 cells), were allowed to adhere to
immobilized L1-Ig6 or to L1-Ig6 containing the
mutated sequences RGDfi KGE or RGDfi RGA.
Adhesion was performed in the presence of Ca21
(2 mM), Mg21 (2 mM), and Mn21 (0.4 mM), or in
the presence of Mg21 (1 mM) alone, or Mn21
alone (0.4 mM). Some cells were pretreated with
antibody to human aIIbb3 (mAb LJ-CP8; 80 mg/
ml). After 40 min, non-adherent cells were re-
moved by washing and the remaining adherent
cells counted per unit area with a 315 high pow-
ered objective. The level of control adhesion
achieved on the wild-type fusion protein was
taken as 100%. In the case of wild-type and
sorted endothelial cells this was equivalent to 168 and 127 adherent cells per field, respectively, in the case of the wild-type CHO cells
this was equivalent to 82 (mixed cations) and 203 (Mn21 alone) adherent cells per field and in the case of CHO cells bearing active aIIbb3
this was equivalent to 224 cells per field. Experimental treatments were performed in triplicate with a minimum of four areas counted
per well. Results are expressed as a percent of the adhesion observed on wild-type L1-Ig6. Error bars represent 61 SD.
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ther breast or lung tumors suggesting that induction of
vascular L1 may be tissue or organ specific.
Interestingly, expression of vascular L1 was also ob-
served in synovial tissues obtained from three out of five
patients diagnosed with rheumatoid arthritis (Fig. 10 H).
In a preliminary study, L1 was also detected on vessels in
psoriatic skin (not shown). Furthermore, whereas we de-
tected little or no L1 expression on cultured human der-
mal microvascular endothelial cells (Clonetics) we did de-
tect significant L1 levels on the surface of the ECV304
endothelial cell line (data not shown). Together these find-
ings may indicate that de novo L1 expression can be in-
duced on endothelial cells as a result of stimulation by spe-
cific, tumor-associated or inflammatory cytokines. Such
vascular L1 may then function as a receptor either for it-
self or for the vascular and platelet integrins identified in
this study.
Discussion
In this work we have detailed the interaction between a
single Ig-like domain within L1 and multiple integrins in-
cluding avb3, avb1, a5b1, and aIIbb3. To our knowledge this
is the first observation that both avb1 and aIIbb3 can inter-
act with a member of the IgSF. Indeed, L1 may be unique
within this family in its capacity to interact with multiple
RGD-dependent integrins. Key structural and regulatory
issues have also been addressed including the central im-
portance of a single RGD motif and the critical regulatory
effect of physiological levels of calcium. Based on these
novel integrin–CAM interactions, and the novel observa-
tion that L1 can be expressed on blood vessels under vari-
ous pathogenic conditions, we propose that L1 may have
an expanded and unexpected role in various vascular and
thrombogenic processes.
The b3 and b1 integrins identified in this study as hetero-
philic receptors for the sixth Ig-like domain of L1 share a
collective ability to recognize RGD motifs within their re-
spective ligands (D’Souza et al., 1991; Haas and Plow, 1994;
Marshall et al., 1995). In this regard, the single RGD se-
quence present in L1-Ig6 (Reid and Hemperly, 1992) would
appear to be a legitimate putative recognition motif. How-
ever, it is also apparent that the conformational and se-
quential environment of a given RGD site and its accessi-
bility will ultimately dictate whether it can truly function
as a recognition motif for a given integrin. Furthermore, it
is now widely documented that non-RGD motifs can also
be recognized by avb3, a5b1, and aIIbb3 (Koivunen et al.,
1994). To demonstrate definitively that the single RGD se-
quence present in human L1 is indeed critical for binding
Figure 10. L1 expression can be induced on
blood vessels. L1 expression associated with
vessels proximal to a squamous cell carci-
noma (A and B). L1 staining was performed
using the anti-L1 mAb 5G3 and the substrate
AEC to give a red stain. L1 is evident on the
small vessels in the dermis (arrows). Vessels
proximal to the tumor also expressed avb3: a
marker of angiogenic blood vessels (C).
Staining for avb3 was performed using
LM609 and the substrate AEC to give a red
stain. Vascular L1 and avb3 expression could
be colocalized on a subset of vessels (D and
E). Vessels staining for avb3 are red (AEC),
whereas vessels also costaining with L1 (ar-
row) are darker brown to blue-black (AEC
and VIP). Angiogenic vessels expressing L1
were detected in normal dermis between the
tumor mass (left arrow) and the epidermis
(right arrow) (F). The tumor and epidermis
are stained for cytokeratin (F). Vessels in the
dermis of normal human skin were found to
be negative or very weakly positive for L1
(G). Vessels in synovial tissue derived from
the joint of a patient with rheumatoid arthri-
tis also showed evidence of L1 expression
(H). L1 staining was performed using the
anti-L1 antibody 5G3 and the substrate AEC
to give a red stain. Bars: (A) 100 mm; (B) 50
mm; (C and D) 20 mm; (E) 25 mm; (F) 200
mm; (G and H) 100 mm.
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by avb3, avb1, a5b1, and aIIbb3 we demonstrate that two
mutations of this site in L1-Ig6 reduce or abrogate binding
by all four of these integrins. Furthermore we demonstrate
that a L1-RGD peptide with the relevant flanking se-
quences (i.e., PSITWRGDGRDLQEL) is effective both
as an immobilized substrate and as a soluble inhibitor for
all of the integrins identified.
As stated, the sequence environment of a given RGD
site is important in determining the strength and specific-
ity of integrin interactions (Kunicki et al., 1997). In the
case of L1, the RGD site is flanked by both a tryptophan
and a glycine (i.e., WRGDG). In this regard, phage display
libraries have identified numerous avb3 and a5b1 peptide
ligands that include a glycine residue COOH-terminal to
the RGD (Healy et al., 1995; and Koivunen et al., 1994).
Interestingly, peptides with a strong affinity for aIIbb3 gen-
erally have a large hydrophobic residue COOH-terminal
to the RGD (O’Neil et al., 1992). This preference may ex-
plain why at low concentrations our L1 peptide was more
efficient at supporting attachment via avb3 than via aIIbb3
(data not shown). Integrin-binding peptides containing a
tryptophan residue NH2-terminal to the RGD have rarely
been identified by phage display libraries, but one has been
reported with specificity for avb3 (Healy et al., 1995). It is
interesting to note, that although we detected significant
avb5 expression on the ECV304 endothelial cells used in
this study (data not shown), we found no evidence for an
interaction between L1-Ig6 (or the L1-RGD peptide) and
this RGD-dependent integrin (data not shown). This
would suggest that the sequence environment of the RGD
site in L1 is not suitable for recognition by avb5.
The conformational or stereochemical presentation of
the RGD site is also a key element in dictating receptor
recognition and affinity. Secondary structural analysis of
RGD recognition motifs in fibronectin (FNIII10) and Foot
and Mouth Disease Virus support an emerging model of
the RGD being presented at the apex of a flexible loop
that extends outwards from the protein core. The side
chains of Arg and Asp are purported to face away from
each other and are flexible enough to adopt the proper
conformation for high affinity integrin binding (Haas and
Plow, 1994). By using a combination of electron micro-
scopic analysis and computer-assisted modeling, Drescher
et al. (1996) conclude that the RGD sites of murine L1,
and the single conserved RGD motif of human L1, are ex-
posed at the molecular surface in a loop or turn between
two b-strands. Furthermore they suggest that in the con-
text of the whole molecule, the sixth Ig-like domain of L1
possesses greater surface hydrophobicity than the other
Ig-like domains suggesting that it, and contained RGD
site(s), can participate in intermolecular interactions.
As a general rule, all integrins require divalent cations
for ligand recognition (D’Souza et al., 1994) and two po-
tential mechanisms have been proposed for this depen-
dence. First, specific cations may induce a conformational
change in the integrin that favors ligand binding (Mould
et al., 1995). Second, the cation may be required to form a
ternary complex with the ligand (e.g., RGD) and the inte-
grin; this complex is envisaged to be an unstable but requi-
site intermediate with the cation eventually being dis-
placed as the ligand–receptor complex stabilizes (D’Souza
et al., 1994). Irrespective of the mechanism, it is now well
documented that different divalent cations can dramati-
cally and differentially influence integrin-binding affinity
and selection. The findings of this study provide a case in
point. Thus, whereas we observed that Ca21 is able to sup-
port a limited interaction between L1 and avb3 or aIIbb3,
this same cation profoundly suppressed a Mn21-dependent
interaction with a5b1 or avb1. It is important to note, that
such a dichotomy between these b1 integrins and the b3 in-
tegrins has been documented for other ligands. Thus, Ca21
has been shown to support both avb3 or aIIbb3 attachment
to RGD peptides or vitronectin (Kirchhofer, 1991; Sue-
hiro et al., 1996), whereas this same cation suppresses the
attachment of a5b1 and avb1 to fibronectin and an RGD
peptide, respectively (Kirchhofer, 1991; Mould et al., 1995).
Recently, Suehiro et al. (1996) described a novel classifica-
tion for defining b3 ligands depending upon their ability to
support the attachment of avb3 and/or aIIbb3 in the pres-
ence of different cations. Thus, class I b3 ligands should be
able to support attachment of both integrins either in the
presence of Ca21 or Mn21. A class II ligand will also sup-
port attachment of aIIbb3 in the presence of either Ca21 or
Mn21, but avb3 attachment is suppressed by Ca21. Finally,
class III ligands bind exclusively to aIIbb3 under all cation
conditions, whereas class IV ligands bind exclusively to
avb3. According to this classification scheme we propose
that L1 is a novel class I ligand for b3 integrins, together
with vitronectin, RGD peptides and disintegrin group A
(Suehiro et al., 1996).
From the findings presented it is probable that Ca21 will
act as a potent physiological regulator of L1–integrin in-
teractions. Thus, given the presence or absence of a given
integrin, physiological calcium concentrations are likely to
favor a hierarchy of L1–integrin interaction such that avb3
or activated aIIbb3 . avb1 . a5b1. This hierarchy is likely
to be further compounded by transnegative dominance, a
recently described phenomenon in which the ligation of a
b3 integrin has been shown to suppress the function of a b1
integrin (Diaz-Gonzalez et al., 1996). It could legitimately
be argued from our data that physiological levels of cal-
cium would effectively preclude an interaction between
a5b1 and L1-Ig6. However, it is important to note that an
interaction between a5b1 and murine L1 has been observed
in the presence of calcium but only after an undefined acti-
vational event after ligation of CD24 (heat stable antigen)
(Kadmon et al., 1995). Thus, a5b1 may indeed have a phys-
iological role in L1 binding, but it is likely to be regulated
by a requirement for additional activational signals.
The observation that L1 can support an RGD-dependent
interaction with avb3 confirms our earlier study that dem-
onstrated that melanoma cells can interact with either full-
length L1 or an L1 fusion protein (L1-Ig4-6) via avb3 (Mont-
gomery et al., 1996). The interaction between human L1
and avb3 has also been confirmed using lymphocytic cell
lines (Ebeling et al., 1996). The finding that human L1-Ig6
can also interact with aIIbb3, avb1, and a5b1 has not (to our
knowledge) been reported, and significantly expands the
potential repertoire of heterophilic L1 interactions that
this CAM can support and the range of cell types that may
be involved. It is important to note that, contrary to our
findings, a previous study did not detect any significant in-
teraction between human L1 and a5b1 (Ebeling et al., 1996).
The most obvious explanation for this is the strict cation
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requirement of this interaction and perhaps transnegative
dominance by avb3. It should also be noted that our CHO
cells express very high levels of a5b1. The observation that
human L1 can interact with a5b1 is, however, in agreement
with a report demonstrating an interaction between this
integrin and murine L1 (Ruppert et al., 1995). In this re-
gard, it is noteworthy that the sixth Ig-like domain of mu-
rine L1 contains an additional RGD sequence (LGD in
human L1) and that this sequence, like the human motif,
may well be available for interaction on an exposed loop
(Drescher et al., 1996). It is conceivable that the absence
of this second RGD sequence in humans may make it a
less favorable ligand for a5b1. However, it is also of inter-
est that human L1 retains some additional non-RGD tri-
peptide sequences such as NGR (fibronectin [FN]-like do-
main 3), STF (FN-like domain 2), and ETA (Ig-like
domain 4), which if exposed in the right stereochemical
configuration, could augment the interaction between L1
and a5b1. Thus, all three of these tripeptide sequences
have been identified as important for the interaction of
non-RGD, 7-mer peptides with a5b1 (Koivunen et al., 1993).
L1 and the integrin counter receptors identified in this
study are expressed on multiple cell types of diverse histo-
logical origin. This suggests the potential for a plethora of
interactions and functions that have yet to be described.
This is especially true given the observation that L1 ex-
pression is not strictly confined to cells of the nervous sys-
tem. Thus, we and others have recently described L1 ex-
pression on human cells of both myelomonocytic and
lymphoid origin (Ebeling et al., 1996; Pancook et al., 1997).
L1 has also been described on epithelial cells of the intes-
tine and urogenital tract (Thor et al., 1987; Kowitz et al.,
1992; Kujat et al., 1995) and on transformed cells of di-
verse histological origin, including melanoma, neuroblas-
toma, embryonal carcinoma, osteogenic sarcoma, squamous
lung carcinoma, squamous skin carcinoma, pheochromo-
cytoma, rhabdomyosarcoma and retinoblastoma cell lines
(Mujoo et al., 1986; Linnemann et al., 1989; Reid and
Hemperly, 1992). Finally, in this study we have also shown
that L1 expression can be induced on certain endothelial
cells. This said, however, the extent to which L1-Ig6–inte-
grin pairing contributes to either homotypic or heterotypic
cell–cell interaction among these diverse cell types re-
mains to be determined. It is important to note that Rup-
pert et al. (1995) have demonstrated that the interaction
between murine L1 and a5b1 can promote significant ho-
motypic cell aggregation. It is also of interest that L1–inte-
grin pairing may be modulated by other molecules that as-
sociate with L1 in the plane of the membrane such as
CD24 (Kadmon et al., 1995; Ruppert et al., 1995). Con-
ceivably, different cis interactions involving L1 may steri-
cally or conformationally alter the accessibility of the RGD
site thereby regulating L1–integrin interactions.
In the context of L1–integrin interactions, it is important
to note, that L1 may be equally or more relevant as a sub-
strate adhesion molecule. Thus, a number of studies have
described incorporation of shed L1 into the occluding ex-
tracellular matrix (ECM). In the adrenal medulla, for ex-
ample, L1 immunoreactivity has been found in the ECM
adjacent to chromaffin cells (Poltorak et al., 1990). Martini
and Schachner (1986) have reported L1 expression in
basement membranes associated with murine Schwann
cells and in association with collagen fibrils of the endo-
neurium, and we have previously reported L1 expression
associated with strands of intra-tumor laminin (Montgom-
ery et al., 1996). Given these reports and our current find-
ings, it is likely that deposition of this CAM will signifi-
cantly alter the microenvironment of a cell to favor the
kind of integrin interactions described in this study.
As stated, the capacity of L1 to interact with multiple in-
tegrins on cells of diverse histological origin may lead to a
plethora of interactions that will add to the functional sig-
nificance of this CAM. Two examples of this are provided
in this study. First, we have demonstrated that L1-Ig6 can
support significant platelet adhesion via aIIbb3. Given the
expression of L1 on endothelial cells, and myelomonocytic
cells (Ebeling et al., 1996; Pancook et al., 1997), and the
capacity of L1 to associate with basement membrane com-
ponents (e.g., Laminin; Hall et al., 1997), one could predict
a role for L1 in thrombogenic processes that involve these
cell types or structures. Since L1 is also highly expressed
on many neuroectodermal tumors, it may be that an inter-
action between L1 and active aIIbb3 will contribute to tu-
mor-associated thrombosis: a process thought to be impor-
tant for the lodgment step of hematogenous metastasis
(Felding-Habermann et al., 1996). Second, we have also
demonstrated a novel interaction between L1-Ig6 and en-
dothelial cells via either vascular avb3 or avb1. It is con-
ceivable that these interactions will contribute to the roll-
ing, arrest, and/or attachment of L1-expressing cells on, or
to, endothelium. This possibility is particularly intriguing
given the expression of L1 on trafficking immune cells and
metastatic tumor cell lines (Linnemann et al., 1989; Reid
and Hemperly, 1992; Ebeling et al., 1996; Pancook et al.,
1997). Our observation that L1 expression can be induced
on blood vessels associated with certain neoplastic or in-
flammatory diseases may indicate a role for L1–integrin or
L1–L1 interactions in the maturation of new blood vessels
and/or reflect an induction of de novo L1 expression by in-
flammatory or tumor-associated cytokines.
Whereas the focus of this study has been on non-neural
cell types, the data presented may have some interesting
implications for neuronal processes. For example, both
avb3 and avb1 have been implicated in avian neural crest
cell adhesion and migration (Delannet et al., 1994). In a
recent study, Milner et al. (1996) demonstrated the impor-
tance of avb1 for migration by oligodendrocyte precur-
sors. Interestingly, the authors speculate that, among other
ligands, L1 present within axonal tracts might serve as a
potential avb1 ligand, providing a mechanism for guiding
migrating oligodendrocytes. Whereas this is merely specu-
lation, our data clearly support the potential for L1–avb1
interactions during neural development. At this stage, no
evidence yet exists to show that L1–integrin interactions
promote neurite extension or other neuronal processes in-
volving L1; these processes appear to be primarily depen-
dent upon a homophilic interaction. However, consider-
ation needs to be given to the integrin repertoire of the
cell being tested. For example, avb1 is expressed on oligo-
dendrocyte precursors but is lost on differentiation. Simi-
larly, attention needs to be given to the appropriate cation
environment. Thus, it is evident from this study that ex-
pression of avb1 adhesion is dependent upon the presence
of Mn21 but is inhibited by Ca21.
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The findings of this study extend the range and signifi-
cance of L1–integrin interactions and add to our under-
standing of how these heterophilic interactions are regu-
lated. In addition to the documented interaction between
human L1 and avb3, we have demonstrated that this CAM
is a relatively promiscuous ligand, supporting further novel
heterophilic interactions with avb1, a5b1, and aIIbb3. It is
further shown that these integrins share a collective ability
to recognize a single RGD motif in the sixth Ig-like do-
main of human L1 and that the binding of these integrins
to this motif is critically and differentially regulated by
physiological levels of calcium. Based on the novel interac-
tions involving avb1 and aIIbb3 we have shown that the
sixth Ig-like domain of human L1 can support significant
endothelial cell and platelet attachment. Based on these
findings, and the observation that L1 expression can be in-
duced on endothelial cells, we propose an expanded role
for this CAM in vascular and thrombogenic processes.
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